BENGALURU, India — November 21, 2026
India is exploring new opportunities to advance pharmaceutical research by combining its established drug manufacturing capabilities with emerging space technologies, as scientists, biotechnology companies and startups investigate how microgravity could contribute to the development of new medicines.
The initiative reflects India’s ambition to strengthen its position in the global pharmaceutical industry while establishing itself as an important participant in the emerging commercial space research sector.
Widely recognised as the “pharmacy of the world” because of its significant contribution to the production and supply of affordable medicines and vaccines, India is now considering how scientific experiments conducted beyond Earth’s atmosphere could open new possibilities for pharmaceutical innovation.
Researchers believe that microgravity, the condition in which objects experience apparent weightlessness, could offer advantages for studying biological materials and developing improved pharmaceutical formulations.
The opportunity attracted considerable attention at the Bengaluru Tech Summit, which concluded on Thursday, November 19. Scientists, policymakers, biotechnology specialists and space technology entrepreneurs gathered to examine how India’s proposed space station could eventually become an orbital laboratory for advanced biological and pharmaceutical research.
The discussions highlighted the possibility of creating a new industry at the intersection of pharmaceuticals, biotechnology and commercial space exploration.
How microgravity could transform pharmaceutical research
One of the major scientific opportunities associated with space-based pharmaceutical research involves the behaviour of proteins and other biological molecules under microgravity conditions.
On Earth, gravity influences the formation and growth of protein crystals. These crystals are important in pharmaceutical research because studying their structures can help scientists understand how biological molecules function and interact.
In the near-weightless environment of space, certain protein crystals can develop more uniformly than they might under normal terrestrial conditions.
Researchers believe that improved crystal growth could make it easier to examine molecular structures in greater detail, potentially supporting the development of more effective medicines and improved drug formulations.
India’s pharmaceutical industry is already exploring the commercial possibilities of this technology.
Biocon, one of the country’s leading biopharmaceutical companies, sees space-based research as a potential source of innovation that could create new opportunities for drug discovery and intellectual property development.
Kiran Mazumdar-Shaw, the company’s executive chairperson, explained that space technology could provide researchers with opportunities to modify molecular structures and develop products with new characteristics.
“Structures of molecules can be modified using space tech. That could basically also create new intellectual property, new molecules, new functionality,” she said.
The potential applications extend beyond conventional drug manufacturing. Researchers could investigate how biological materials behave in microgravity, potentially identifying molecular structures and processes that are difficult to study under normal conditions.
However, the scientific possibilities still require extensive experimentation before they can translate into commercially available medicines.
India’s ambitious plan for a national space station
India’s interest in space-based biotechnology research is closely connected to its broader ambitions to become a major player in the international space economy.
The International Space Station, which has provided an important platform for scientific research in orbit, is expected to retire around 2030. Governments and private companies are consequently accelerating efforts to develop alternative commercial space stations and orbital research facilities.
India is pursuing its own programme through the proposed Bharatiya Antariksh Station, which is expected to become fully operational by 2035.
The planned facility could provide an important platform for scientific experiments involving pharmaceuticals, biotechnology and other advanced technologies.
At the Bengaluru Tech Summit’s space biotechnology symposium, policymakers and scientists discussed how the proposed station could eventually support international collaboration and attract researchers and commercial organisations interested in conducting experiments in orbit.
Such a facility could strengthen India’s scientific capabilities while creating opportunities for domestic biotechnology companies to participate in the expanding commercial space industry.
Nevertheless, scientists believe pharmaceutical research should not have to wait until the national space station becomes operational.
A S Kiran Kumar, former chairman of the Indian Space Research Organisation (ISRO), said researchers were examining alternative methods of conducting microgravity experiments before India establishes its permanent orbital research infrastructure.
“Now, we are also looking at how we can provide alternate on-ground or parabolic flights … so even before you reach orbit, there are possibilities of doing certain periods, small periods of experiments on microgravity,” he said.
Parabolic flights can produce brief periods of weightlessness by following specially designed flight paths. Such experiments could allow scientists to investigate selected biological processes without having to send every research project into orbit.
Ground-based facilities and other experimental platforms could also help researchers prepare for more sophisticated investigations aboard future space stations.
The approach would enable India to begin developing scientific expertise, commercial partnerships and research capabilities ahead of the completion of its planned orbital facility.
Indian startups explore commercial opportunities in space biotechnology
Beyond government-backed space programmes and established pharmaceutical companies, Indian startups are beginning to identify commercial opportunities in the emerging market for orbital scientific research.
One of the companies pursuing this opportunity is Chennai-based Inbound Aerospace, which is developing services to support microgravity experiments in low-Earth orbit.
Its business model involves transporting scientific research equipment and experimental payloads into space, allowing researchers to conduct investigations under microgravity conditions before safely returning the materials to Earth.
The company is working to make orbital research more accessible to scientific organisations and businesses that may not possess the infrastructure or expertise required to independently organise space missions.
Inbound Aerospace co-founder Abhijit Bhutey explained that the company intends to manage the transportation and recovery of research payloads according to the requirements of its clients.
“Our job is, when the payload is ready, we carry it for them, put it in orbit for up to two months as per the requirement, and then we bring it back safely,” he said.
Bhutey also disclosed that the company has established partnerships with Australian and Japanese businesses specialising in the development of scientific payloads.
These collaborations demonstrate the international dimension of India’s emerging space biotechnology industry.
By connecting domestic research organisations with foreign technology providers, Indian startups could help establish a commercial ecosystem capable of supporting experiments conducted in orbit.
The ability to transport scientific materials into space and return them safely could become particularly important as pharmaceutical companies increasingly explore the potential benefits of microgravity research.
US space infrastructure company identifies India as an important partner
India’s established experience in biomanufacturing is also attracting attention from international companies developing commercial space infrastructure.
Among the organisations monitoring the country’s progress is HabSpace, a United States-based company working on plans for commercial space station infrastructure.
The company believes India’s pharmaceutical and biotechnology industries could provide valuable expertise as private organisations develop the next generation of orbital research facilities.
George Weinmann, HabSpace’s founder and chief executive officer, highlighted the importance of India’s existing manufacturing capabilities in helping international companies understand the requirements of commercial biotechnology research.
“Markets like India that have already established scale in biomanufacturing have a lot to teach us about what it takes and what is needed … to make sure that we are building the right infrastructure,” he said.
The statement reflects growing international interest in combining pharmaceutical manufacturing expertise with commercial space infrastructure.
India’s established biotechnology ecosystem could make it an attractive destination for international partnerships, particularly as companies seek markets with the scientific knowledge and industrial capacity required to support advanced biological research.
Such partnerships could also help Indian startups gain access to international networks, specialised equipment and emerging commercial opportunities.
High costs and regulatory challenges threaten commercial expansion
Despite the enthusiasm surrounding space-based pharmaceutical research, commercial manufacturing of medicines in orbit remains at an early stage.
Several challenges must be addressed before the technology can become a commercially viable alternative or complement to conventional pharmaceutical research.
One major obstacle is the cost of transporting research equipment and biological materials into space and subsequently returning them to Earth.
Launching scientific payloads requires specialised infrastructure, technical expertise and substantial financial investment. These expenses could limit participation to organisations with sufficient resources unless transportation costs decline significantly.
Regulatory requirements also present difficulties.
Pharmaceutical products must undergo rigorous scientific evaluation and regulatory approval before they can be distributed for medical use. Medicines developed or manufactured under microgravity conditions would still need to demonstrate their safety, quality and effectiveness.
Researchers and companies must therefore establish appropriate procedures for conducting experiments, handling biological materials and assessing the pharmaceutical products generated through orbital research.
The limited availability of commercial orbital infrastructure is another significant constraint.
Although several organisations are developing plans for private space stations, the sector still requires considerable investment and technological development before large-scale research operations become routine.
The long timelines involved in building and operating such facilities could delay the emergence of a profitable space pharmaceutical industry.
Consequently, while the commercialisation of medicines developed in orbit may still be several years away, India is positioning itself to participate in a sector that could eventually create new opportunities for pharmaceutical innovation.
India seeks a stronger position in the global space economy
India’s interest in pharmaceutical research beyond Earth reflects a broader strategy to diversify its space programme and expand the commercial applications of its scientific capabilities.
The country has already developed a substantial pharmaceutical manufacturing industry and established a growing presence in space exploration.
Combining these strengths could create opportunities for domestic businesses to participate in international biotechnology research, space transportation and the development of orbital laboratories.
The proposed Bharatiya Antariksh Station could become an important component of this strategy by providing a future platform for experiments that require extended periods in microgravity.
In the meantime, partnerships involving Indian startups, established pharmaceutical companies and international space technology developers could help build the scientific and commercial foundations necessary for the industry.
The discussions at the Bengaluru Tech Summit indicate that India is looking beyond traditional pharmaceutical manufacturing towards more advanced research opportunities.
Although significant scientific, financial and regulatory obstacles remain, the country’s growing interest in space-based biotechnology suggests that pharmaceutical innovation could become another important dimension of its expanding space ambitions.

Leave a Reply